Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

bio pharma

  • Home
  •  
  • bio pharma



  • Most Read
  • Latest Comments
  • Paradigm clinical trial results identify breakthrough in fight against osteoarthritis
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Paradigm clinical trial results identify breakthrough in fight against osteoarthritis
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • Paradigm clinical trial results identify breakthrough in fight against osteoarthritis
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Paradigm clinical trial results identify breakthrough in fight against osteoarthritis
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • Paradigm clinical trial results identify breakthrough in fight against osteoarthritis
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Study results emerge for Proteomics International Laboratories’ latest cancer diagnostic test
    Study results emerge for Proteomics International Laboratories’ latest cancer diagnostic test
    • News

  • Paradigm’s study could give options to those with this rare incurable disease
    Paradigm’s study could give options to those with this rare incurable disease
    • News

  • Q&A: Paradigm to answer FDA questions to achieve Investigational New Drug status
    Q&A: Paradigm to answer FDA questions to achieve Investigational New Drug status
    • News

  • Paradigm eyes FDA and TGA submission as patient data confirms major joint pain reduction
    Paradigm eyes FDA and TGA submission as patient data confirms major joint pain reduction
    • News

  • Imagion and Siemens Healthineers to collaborate on cancer detection agent
    Imagion and Siemens Healthineers to collaborate on cancer detection agent
    • News

  • Paradigm clinical trial results identify breakthrough in fight against osteoarthritis
    • News

    Paradigm clinical trial results identify breakthrough in fight against osteoarthritis

    Osteoarthritis sufferers could soon receive effective pain relief and reduced onset from the degenerative disease after Paradigm Biopharmaceuticals (ASX: PAR) reported breakthrough clinical trial results which identified a significant reduction of pain levels from participants using their Zilosul product.  The 53-day clinical trial saw testing of the injectable Pentosan-based treatment (iPPS) which demonstrated a conclusive

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.